Topic

Oxbryta (voxelotor)

A collection of 13 issues

How to Handle Oxbryta (Voxelotor) Coverage Denial by Cigna in Texas: Appeals Guide After FDA Withdrawal

Answer Box: Oxbryta Coverage in Texas Oxbryta (voxelotor) was voluntarily withdrawn from the U.S. market in September 2024 due to safety concerns, making coverage appeals moot for new prescriptions. If you're currently taking Oxbryta, work with your hematologist immediately to transition to alternative sickle cell treatments like

How to Get Oxbryta (Voxelotor) Covered by Cigna in New York: 2024 Withdrawal Update and Alternative Paths

Answer Box: Critical Update on Oxbryta (Voxelotor) Coverage Important: Oxbryta (voxelotor) was voluntarily withdrawn from the U.S. market by Pfizer in September 2024 due to safety concerns and insufficient clinical benefit. The drug is no longer FDA-approved and cannot be prescribed or covered by any U.S. insurer, including

Getting Oxbryta (Voxelotor) Covered by Aetna CVS Health in Virginia: 2024 Updates, Appeals, and Alternatives

Quick Answer: Oxbryta Coverage Status in Virginia Important Update: Oxbryta (voxelotor) is no longer FDA-approved in the United States as of 2024. Pfizer withdrew the drug following a confirmatory evidence review. If you're in Virginia with Aetna CVS Health coverage and need sickle cell disease treatment, focus on